EBS
Emergent BioSolutions Inc.
NYSE · USHealthcareDrug Manufacturers - Specialty & Generic
$7.69+0.79%
Price as of Jul 20, 2026
EBS financials
Emergent BioSolutions Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $742.9M | $1.0B | $1.0B | $1.1B |
| Cost of revenue | $392.3M | $668.2M | $689.3M | $644.5M |
| Gross profit | $350.6M | $375.4M | $360.0M | $473.0M |
| Operating expenses | $240.4M | $484.1M | $1.1B | $643.0M |
| Operating income | $110.2M | -$108.7M | -$726.4M | -$170.0M |
| Net income | $52.6M | -$190.6M | -$760.5M | -$211.6M |
| EBITDA | $240.4M | $53.4M | -$47.0M | $15.7M |
| Basic EPS | $0.98 | $-3.60 | $-14.85 | $-4.22 |
| Diluted EPS | $0.93 | $-3.60 | $-14.85 | $-4.22 |
| Balance sheet | ||||
| Cash & equivalents | $205.4M | $99.5M | $111.7M | $642.6M |
| Total assets | $1.3B | $1.4B | $1.8B | $3.2B |
| Total liabilities | $796.0M | $906.9M | $1.2B | $1.8B |
| Stockholders’ equity | $522.6M | $482.8M | $649.3M | $1.4B |
| Total debt | $572.1M | $676.1M | $860.2M | $1.4B |
| Net debt | $366.7M | $576.6M | $748.5M | $783.8M |
| Cash flow | ||||
| Operating cash flow | $170.6M | $58.7M | -$206.3M | -$34.1M |
| Capital expenditure | -$13.8M | -$22.9M | -$51.6M | -$115.8M |
| Free cash flow | $156.8M | $35.8M | -$257.9M | -$149.9M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$24.9M | $0.00 | $0.00 | -$82.1M |